Evidence map›Paper›PMID 42604116›Full record

ArticleMolecular therapy. Oncology2026

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

Zili Zhen, Qiang Gao, Yong Ai, Zhihong Qian, Yukui Shang, Yafang Deng, Shuai Chen, Xin Ni, Wei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zili ZhenIDG/McGovern Institute for Brain Research, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Qiang GaoDepartment of Neurosurgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Yong AiIDG/McGovern Institute for Brain Research, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Zhihong QianThe State Key Laboratory for Complex, Severe, and Rare Diseases, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing 100084, China.
Yukui ShangThe State Key Laboratory for Complex, Severe, and Rare Diseases, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing 100084, China.
Yafang DengDepartment of Internal Medicine, Peking Union Medical College Hospital, Beijing 100730, China.
Shuai ChenNeurological Center, Beijing Children's Hospital Shunyi Women's and Children's Hospital, Beijing 101300, China.
Xin NiNational Center for Pediatric Cancer Surveillance, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Wei ZhangIDG/McGovern Institute for Brain Research, School of Life Sciences, Tsinghua University, Beijing 100084, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse midline glioma (DMG) is an aggressive malignancy driven by the H3K27M oncohistone, leading to global epigenetic dysregulation and limited efficacy of single-agent epigenetic therapies. We previously observed clinical benefit from an HDAC/EZH2 inhibitor-based therapeutic regimen, but the mechanistic basis was unclear. A panel of patient-derived DMG glioma stem cell (GSC) cultures from brainstem and spinal cord tumors was used for drug-response and functional assays, with representative models further analyzed for transcriptomic alterations, cell-cycle distribution, global histone-modification changes, self-renewal, and

Indexed as

cell-cycle arrestdiffuse midline gliomaepigenetic therapyEZH2 inhibitorglioma stem cellHDAC inhibitorpanobinostattazemetostattherapeutic synergy

Identifiers

PMID42604116
PMCPMC13476686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.